Literature DB >> 1778891

Overview of liposomes.

G Gregoriadis1.   

Abstract

Many of the problems associated with conventional drug therapy may be circumvented by the use of delivery systems which, in a variety of ways, will optimize drug action. Among the systems being investigated, liposomes hold considerable promise. Versatility in both the structural characteristics of liposomes and their ability to accommodate a wide range of drugs has contributed to the design of appropriate formulations with optimal pharmacological actions. Areas in which such formulations have been already applied successfully experimentally or clinically, include cancer chemotherapy, antimicrobial therapy and vaccines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1778891     DOI: 10.1093/jac/28.suppl_b.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.

Authors:  Maryam Iman; Zhaohua Huang; Seyedeh Hoda Alavizadeh; Francis C Szoka; Mahmoud R Jaafari
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.

Authors:  E W van Etten; M T ten Kate; S V Snijders; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

4.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

Authors:  V Heinemann; D Bosse; U Jehn; B Kähny; K Wachholz; A Debus; P Scholz; H J Kolb; W Wilmanns
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 7.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

8.  Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

Authors:  J W Lee; M A Amantea; P A Francis; E E Navarro; J Bacher; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential.

Authors:  G Gregoriadis; A T Florence
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 10.  Liposomal formulations of cytotoxic drugs.

Authors:  R Janknegt
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.